These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38532893)

  • 21. Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling.
    Qin T; Liu Z; Wang J; Xia J; Liu S; Jia Y; Liu H; Li K
    Cancer Biol Med; 2020 Aug; 17(3):753-767. PubMed ID: 32944404
    [No Abstract]   [Full Text] [Related]  

  • 22. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 23. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
    Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
    Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
    [TBL] [Abstract][Full Text] [Related]  

  • 24. METTL3 inhibitor STM2457 impairs tumor progression and enhances sensitivity to anlotinib in OSCC.
    Liu L; Zhao T; Zheng S; Tang D; Han H; Yang C; Zheng X; Wang J; Ma J; Wei W; Wang Z; He S; He Q
    Oral Dis; 2024 Feb; ():. PubMed ID: 38376115
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC.
    Wang S; Lou N; Luo R; Hao X; Liu Y; Wang L; Shi Y; Han X
    J Transl Med; 2022 May; 20(1):248. PubMed ID: 35642002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade.
    Yang Q; Ni L; Imani S; Xiang Z; Hai R; Ding R; Fu S; Wu JB; Wen Q
    Cancer Manag Res; 2020; 12():4937-4948. PubMed ID: 32606981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anlotinib exerts potent antileukemic activities in Ph chromosome negative and positive B-cell acute lymphoblastic leukemia via perturbation of PI3K/AKT/mTOR pathway.
    Chen Q; Lai Q; Jiang Y; Yao J; Chen Q; Zhang L; Wang C; Zhou Y; Deng M; Xu B
    Transl Oncol; 2022 Nov; 25():101516. PubMed ID: 35985203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cross-talk between tumor cells and activated fibroblasts mediated by lactate/BDNF/TrkB signaling promotes acquired resistance to anlotinib in human gastric cancer.
    Jin Z; Lu Y; Wu X; Pan T; Yu Z; Hou J; Wu A; Li J; Yang Z; Li C; Yan M; Yan C; Zhu Z; Liu B; Qiu W; Su L
    Redox Biol; 2021 Oct; 46():102076. PubMed ID: 34315112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation.
    Loriot Y; Mordant P; Dorvault N; De la motte Rouge T; Bourhis J; Soria JC; Deutsch E
    Br J Cancer; 2010 Jul; 103(3):347-53. PubMed ID: 20628392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anlotinib Overcomes Multiple Drug Resistant Colorectal Cancer Cells via Inactivating PI3K/AKT Pathway.
    Lan W; Zhao J; Chen W; Shang H; Peng J; Lin J
    Anticancer Agents Med Chem; 2021; 21(15):1987-1995. PubMed ID: 33438566
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib.
    Cao Y; Shan H; Liu M; Liu J; Zhang Z; Xu X; Liu Y; Xu H; Lei H; Yu M; Zhang X; Liu W; Bu Z; Fang Z; Ji Y; Yan H; Gu W; Wu Y
    Cell Death Dis; 2021 Apr; 12(4):396. PubMed ID: 33854043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The TGFβ-miR-499a-SHKBP1 pathway induces resistance to EGFR inhibitors in osteosarcoma cancer stem cell-like cells.
    Wang T; Wang D; Zhang L; Yang P; Wang J; Liu Q; Yan F; Lin F
    J Exp Clin Cancer Res; 2019 May; 38(1):226. PubMed ID: 31138318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiscale modeling reveals angiogenesis-induced drug resistance in brain tumors and predicts a synergistic drug combination targeting EGFR and VEGFR pathways.
    Liang W; Zheng Y; Zhang J; Sun X
    BMC Bioinformatics; 2019 May; 20(Suppl 7):203. PubMed ID: 31074391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
    Wu Y; Zhang T; Liu Y; Wang J; Bi N
    Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C.
    Fang F; Yuan Q
    Oncol Lett; 2022 Feb; 23(2):46. PubMed ID: 34976158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anlotinib Suppresses Oral Squamous Cell Carcinoma Growth and Metastasis by Targeting the RAS Protein to Inhibit the PI3K/Akt Signalling Pathway.
    Lu Y; Lin J; Duan M; Rui Y; Zheng H; Zhu L; Zhu X; Wei J
    Anal Cell Pathol (Amst); 2021; 2021():5228713. PubMed ID: 34926131
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma.
    Li S
    Front Oncol; 2021; 11():664853. PubMed ID: 34094958
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic Antitumor Effects of Anlotinib Combined with Oral 5-Fluorouracil/S-1 via Inhibiting Src/AKT Signaling Pathway in Small-Cell Lung Cancer.
    Xia X; Pi W; Lan Y; Wu X; Lv D; Meng Y; Yang H; Wang W
    Anal Cell Pathol (Amst); 2022; 2022():4484211. PubMed ID: 35757014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A pilot study of anlotinib with third-generation epidermal growth factor receptor tyrosine kinase inhibitors in untreated
    Li T; Chang K; Qiu X; Lai Z; Luo Y; Chen J; Lv W; Lin Z; Pei X; Wu X; Wang X
    Transl Lung Cancer Res; 2023 Jun; 12(6):1256-1263. PubMed ID: 37425401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.